Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Compounding Chemotherapy Market?

The market size for compounding chemotherapy has demonstrated robust growth in the past few years. The market is predicted to expand from $5.74 billion in 2024 to $6.11 billion in 2025, clocking a compound annual growth rate (CAGR) of 6.3%. The historical growth trend can be traced back to factors such as the rising rate of cancer cases, the surging preference for hospital pharmacies, the escalating usage of antineoplastic agents, an increasing emphasis on individualized dosing, as well as the burgeoning importance of oncology specialty clinics.

Expectations are high for a substantial increase in the compounding chemotherapy market size in the approaching years. The market is anticipated to escalate to $7.74 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%. The upturn predicted within this forecast period can be associated with an elevated emphasis on precision medicine, an intensified demand for oral and injectable chemotherapy compounds, an augmented use of hormonal and biologic agents in oncology, an increased focus on curtailing drug waste, and a surging demand for cancer treatments that are targeted. Key trends projected within this forecast period encompass the integration of technology in automated compounding devices, the creation of customized chemotherapy dosing protocols, the development of mobile applications designed to assist with chemotherapy workflow, the incorporation of electronic health records (EHRs) into compounding systems, and the integration of barcode verification within compounding protocols.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp

Which Factor Is Shaping The Future Of The Compounding Chemotherapy Market?

The rise in cancer incidents is projected to boost the growth of the compounding chemotherapy market. Cancer is a collection of diseases typified by uncontrolled proliferation and metastasis of rogue cells in the body. This surge in cancer occurrences is mainly due to unhealthy lifestyle habits such as poor nutrition, physical inactivity, smoking, excessive consumption of alcohol, and long-term exposure to environmental contaminants, all of which notably increase the likelihood of different cancer types development. Compounding chemotherapy contributes to cancer treatment by providing customized medication formulations in line with each patient’s requirements, enhancing effectiveness and reducing side effects. For example, data from the Australian Institute of Health and Welfare from July 2024 revealed that in 2022, 160,570 cancer cases were diagnosed in Australia, indicating a rise of 3,789 cases from 156,781 in 2021. Consequently, the rising prevalence of cancer is fuelling the growth of the compounding chemotherapy market.

What Is The Segment-Wise Breakdown Of The Compounding Chemotherapy Market?

The compounding chemotherapy market covered in this report is segmented –

1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs

2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal

3) By Technology: With Robotic Arms, Without Robotic Arms

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings

Subsegments:

1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors

2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists

3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators

4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors

5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs

Which Trends Are Redefining The Future Landscape Of The Compounding Chemotherapy Industry?

Leading firms in the compounding chemotherapy market are concentrating on the creation of innovative solutions such as automated chemotherapy systems powered by robots. Aiming for precision, safety, and proficiency, these advanced machines offer a personalized approach to cancer treatment by accurately preparing individual chemotherapy doses. The automated processes minimize human error and the risk of contamination. For instance, in February 2024, Israel-based Simplivia Healthcare Ltd. introduced their Smart Compounders Advanced Systems. These systems optimize the preparation process for cytotoxic (chemotherapy) drugs and possess the capability to compound cytostatics and antibodies, managing between 20 to 40 preparations an hour. They also incorporate automatic gravimetric verification and documentation for the certainty of accuracy. Exposure to harmful substances for pharmacy staff is significantly reduced thanks to these systems that smoothly merge into existing laminar airflow (LAF) cabinets or isolators, without the demand for any alterations.

Which Companies Hold The Largest Market Share In The Compounding Chemotherapy Sector?

Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Option Care Health Inc., ICU Medical Inc., Dedalus S.p.A., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, Stokes Healthcare Inc, McGuff Compounding Pharmacy Services Inc., Accord Healthcare Limited, Epicur Pharma LLC, Simplivia Healthcare Ltd., AmerisourceBergen Corporation, Kapsam Health Products Ltd., PharMEDium Services LLC.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report

How Does Regional Performance Compare Across The Compounding Chemotherapy Industry?

North America was the largest region in the compounding chemotherapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25724&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model